Therapeutic Potential of Silver Nanoparticles (AgNPs) as an Antimycobacterial Agent: A Comprehensive Review
Open Access
- 20 November 2024
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1106
Abstract
The uncontrolled emergence of multidrug-resistant mycobacterial strains presents as the primary determinant of the present crisis in antimycobacterial therapeutics and underscores tuberculosis (TB) as a daunting global health concern. There is an urgent requirement for drug development for the treatment of TB. Numerous novel molecules are presently undergoing clinical investigation as part of TB drug development. However, the complex cell wall and the lifecycle of M. tuberculosis within the host pose a significant challenge to the development of new drugs and, therefore, led to a shift in research focus towards alternative antibacterial compounds, notably nanotechnology. A novel approach to TB therapy utilizing silver nanoparticles (AgNPs) holds the potential to address the medical limitations imposed by drug resistance commonly associated with currently available antibiotics. Their broad-spectrum antimicrobial activity presents the utilization of AgNPs as a promising avenue for the development of therapeutics targeting mycobacterial-induced diseases, which can effectively target Mycobacterium tuberculosis, including drug-resistant strains. AgNPs can enhance the effectiveness of traditional antibiotics, potentially leading to better treatment outcomes and a shorter duration of therapy. However, the successful implementation of this complementary strategy is contingent upon addressing several pivotal therapeutic challenges, including suboptimal delivery, variability in intra-macrophagic antimycobacterial effect, and potential toxicity. Future perspectives may involve developing targeted delivery systems that maximize therapeutic effects and minimize side effects, as well as exploring combinations with existing TB medications to enhance treatment outcomes. We have attempted to provide a comprehensive overview of the antimycobacterial activity of AgNPs, and critically analyze the advantages and limitations of employing silver nanoparticles in the treatment of TB.Keywords
This publication has 111 references indexed in Scilit:
- In vitro study on the immunomodulatory effects of differently functionalized silver nanoparticles on human peripheral blood mononuclear cellsJBIC Journal of Biological Inorganic Chemistry, 2021
- Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosisApoptosis, 2019
- Commercial Yeast Extracts Mediated Green Synthesis of Silver Chloride Nanoparticles and their Anti-mycobacterial ActivityJournal of Cluster Science, 2019
- Antibacterial Activity of Silver Nanoparticles: Structural EffectsAdvanced Healthcare Materials, 2018
- Exposure to silver nanoparticles affects viability and function of natural killer cells, mostly via the release of ionsCell Biology and Toxicology, 2017
- Mutation of environmental mycobacteria to resist silver nanoparticles also confers resistance to a common antibioticBioMetals, 2014
- Silver nanoparticle induced cytotoxicity, oxidative stress, and DNA damage in CHO cellsJournal of Nanoparticle Research, 2013
- Nature-inspired Novel Drug Design Paradigm Using Nanosilver: Efficacy on Multi-Drug-Resistant Clinical Isolates of TuberculosisCurrent Microbiology, 2010
- Comparative toxicity study of Ag, Au, and Ag–Au bimetallic nanoparticles on Daphnia magnaAnalytical and Bioanalytical Chemistry, 2010
- Cytotoxicity and Immunological Response of Gold and Silver Nanoparticles of Different SizesSmall, 2009